ArticleCureus2026
Immunoglobulin G4 (IgG4)-Related Lung Disease Mimicking Pulmonary Malignancy: A Case Report With Histopathological Characterisation and Review of Diagnostic Criteria.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a systemic fibroinflammatory condition with highly variable pulmonary manifestations that frequently overlaps clinically, radiologically, and metabolically with primary malignancy, granulomatous disease, and vasculitis. Tissue diagnosis with immunohistochemical quantification of IgG4-positive plasma cells remains the diagnostic cornerstone. A 50-year-old male ex-smoker presented with a two-month history of progressive cough, dyspnoea, chest pain, and 8 kg of unintentional weight loss. Examination revealed digital clubbing and bilateral crepitations. Laboratory investigations showed mild normocytic anaemia, leukocytosis with neutrophilic predominance, and a markedly elevated erythrocyte sedimentation rate of 109 mm/h. Serum IgG4 was elevated at 2.23 g/L (reference range <1.35 g/L). Total IgG and comprehensive autoimmune and infectious serology were unremarkable. Positron Emission Tomography-Computed Tomography (PET-CT) demonstrated multiple bilateral pulmonary nodules (some cavitating) with an exceptionally high maximal standardised uptake value (SUVmax 20.1) and mediastinal lymphadenopathy, prompting strong initial suspicion of primary pulmonary malignancy. CT-guided lung biopsy revealed dense storiform fibrosis, a lymphoplasmacytic infiltrate rich in eosinophils, and features of fibroinflammatory change; however, immunohistochemistry did not demonstrate an increased number of IgG4-positive plasma cells, and formal histopathological criteria for IgG4-related disease were not fulfilled. In the context of compatible clinical, radiological, and serological findings, a diagnosis of probable IgG4-related lung disease was considered. Oral prednisolone at 0.6 mg/kg/day produced substantial clinical and radiological improvement, with near-complete resolution of opacities and reduction in nodule size by six months. This case illustrates the diagnostic pitfalls of IgG4-related lung disease, which can produce exceptionally high 18F-fluorodeoxyglucose (FDG) avidity on PET-CT, cavitating nodules, and constitutional features indistinguishable from malignancy. Histopathological evaluation with formal IgG4 cell quantification and ratio calculation is essential for accurate diagnosis; however, cases with supportive clinicoradiological features but non-diagnostic immunostaining may still pose significant diagnostic challenges. Early corticosteroid treatment yields excellent outcomes and prevents unnecessary oncological intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.